## ABSTRACT OF THE DISCLOSURE

[0100] Novel cyclic polyamine compounds of the form

$$\begin{array}{c|c}
 & O \\
 & M & N & A_1 \\
 & N & Y & A_2 \\
 & N & N & A_2
\end{array}$$

$$\begin{array}{c}
 & A_1 \\
 & A_2 \\
 & A_2
\end{array}$$

where A<sub>1</sub>, each A<sub>2</sub> (if present), and A<sub>3</sub> are independently selected from C<sub>1</sub>-C<sub>8</sub> alkyl, where each Y is independently selected from H or C<sub>1</sub>-C<sub>4</sub> alkyl, where M is selected from C<sub>1</sub>-C<sub>4</sub> alkyl, where k is 0, 2, or 3, and where R is selected from C<sub>1</sub>-C<sub>32</sub> alkyl, as well as all stereoisomers and salts thereof, are disclosed. Additional compounds where k is 1 and A<sub>2</sub> is independently selected from C<sub>1</sub>-C<sub>3</sub> alkyl or C<sub>5</sub>-C<sub>8</sub> alkyl are also disclosed. Cyclic polyamines, where the amide group is reduced to a secondary amino group, and various derivatives of these compounds, are also described. Synthetic methods for the compounds are described. The compounds are useful for treating diseases caused by uncontrolled proliferation of cells, such as cancer, especially prostate cancer, and for inducing intracellular ATP hydrolysis for treatment of other disorders.